New asthma therapy findings from J. Corren and co-researchers published

Investigators publish new data in the report "Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma." According to a study from the United States, "The addition of the long-acting beta(2)-adrenergic agonist formoterol to low-to moderate-dose budesonide has shown clinical efficacy in patients with persistent asthma. Combination therapy with budesonide/formoterol in 1 pressurized metered-dose inhaler (pMDI) has been found to have greater efficacy than its monocomponents in patients with moderate to severe...

Want to see the full article?

• Purchase this article for only $3.00